Latest Fungal diseases Stories
PALO ALTO, Calif., Feb. 18 /PRNewswire/ -- TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced the appointment of Mark W. Davis as Vice President of Clinical Development. In this position, Mr. Davis will lead TOPICA's clinical development activities for luliconazole, its lead product candidate, for the treatment of onychomycosis (nail and nail bed fungal infections) and tinea pedis (athlete's foot). The company expects to initiate a Phase 1/2a trial of...
PALO ALTO, Calif., Feb. 1 /PRNewswire/ -- TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis (nail and nail bed fungal infections). The company plans to initiate a Phase 1/2 trial in the first quarter. Luliconazole is one of the most potent and broad-spectrum...
Midwife toads that live in the mountains are highly likely to die from a serious fungal infection, called chytridiomycosis, whereas their infected relatives in the lowlands are not, according to new research published Jan. 24 in Ecology Letters.The authors of the study, from Imperial College London, the Zoological Society of London and the BiodivERsA project RACE, say their findings suggest conservationists may be able to limit the impact of the disease in the mountains by ensuring tourists...
PALO ALTO, Calif., Jan. 25 /PRNewswire/ -- TOPICA Pharmaceuticals today announced that Greg Vontz, president and CEO, will present at BioPartnering North America on Monday, January 25, at 2:45 p.m. Pacific Time at the Westin Bayshore Resort in Vancouver, BC. During the presentations, Mr. Vontz will provide an overview of TOPICA and its clinical development plans for luliconazole, one of the most potent and broad spectrum topical antifungal agents, for the treatment of onychomycosis (fungal...
An estimated 25,000 Americans develop severe fungal infections each year, leading to 10,000 deaths despite the use of anti-fungal drugs. The associated cost to the U.S. health care system has been estimated at $1 billion a year.Now two Syracuse University scientists have developed new brominated furanones that exhibit powerful anti-fungal properties.The most virulent fungus is Candida albicans, which is carried by about 75 percent of the public. Typically the fungus is harmless but, in...
 A team of researchers at the Worcester Polytechnic Institute (WPI) Life Sciences and Bioengineering Center at Gateway Park has developed a new model system to study fungal infections. The system can be a powerful tool for screening potential drug targets for conditions like thrush, athlete's foot and vaginal yeast infections, which affect millions of people each year but are difficult to treat with existing medications. Using the new model, the researchers also identified a gene that may...
EMERYVILLE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia. "This model tests both the penetration of the nail as well as the effectiveness of the compounds...
Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments.The two separate studies, published today in the New England Journal of Medicine, mark a significant step in the understanding of genetic susceptibility to fungal diseases. The findings have implications for people...
PALO ALTO, Calif., Oct. 22 /PRNewswire/ -- TOPICA Pharmaceuticals today announced that Greg Vontz, president and CEO, will present at the following investor conferences next week: The 2009 Life Sciences and Healthcare Venture Summit on Tuesday, October 27, at 11:40 a.m. Eastern Time at the Digital Sandbox Network Event Center at 55 Broad Street in New York.The 8th Annual BIO Investor Forum on Thursday, October 29 at 9:30 a.m. Pacific Time at the Palace Hotel in San Francisco.During the...
Einstein research offers theory on protective effect of being warm-bloodedThe fact that they eat a lot "“ and often "“ may explain why most people and other mammals are protected from the majority of fungal pathogens, according to research from Albert Einstein College of Medicine of Yeshiva University.The research, published in the Journal of Infectious Diseases, showed that the elevated body temperature of mammals "“ the familiar 98.6o F or 37o C in people "“ is too high for the vast...
